The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Open accessAbstract
To evaluate whether the epidermal growth factor receptor (EGFR), K-Ras and PTEN, all members of the EGFR signalling pathway, may affect the clinical response in cetuximab-treated metastatic colorectal cancer (mCRC) patients. Twenty-seven cetuximab-treated mCRC patients were evaluated for drug response and investigated for EGFR protein expression and gene status, K-Ras mutational status and PTEN protein expression. Ten patients achieved a partial response (PR) to cetuximab-based therapy. All 27 patients showed EGFR protein overexpression. Epidermal growth factor receptor gene amplification was observed in eight out of 27 (30%) and chromosome 7 marked polysomy in 16 (59%) patients. Partial response was observed in six out of eight patients with EGFR gene amplification, four out of 16 with marked polysomy and none out of three with eusomy (P<0.05). The K-Ras wild-type sequence was observed in 17 patients, and nine of them experienced a PR. Conversely, K-Ras was mutated in 10 cases, of which one patient experienced a PR (P<0.05). The PTEN protein was normally expressed in 16 patients, and 10 of them achieved a PR. In contrast, no benefit was documented in 11 patients with loss of PTEN activity (P<0.001). Patients with EGFR gene amplification or chromosome 7 marked polysomy respond to cetuximab. In addition to K-Ras mutations, we demonstrate for the first time that the loss of PTEN protein expression is associated with nonresponsiveness to cetuximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PTEN inactivation (usually assessed as lack of protein expression) has been associated with nonresponsiveness to anti-EGFR moAbs in mCRC patients in several studies [19, 73, 75, 76]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [75]
In the citing paper
“Patients with PTEN-negative status showed a worse response rate and shorter progression-free survival (PFS) than those with PTEN-positive status [106, 108, 109].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Research works printed but not linked: 4
- Jennis A, Polikoff J, Mitchell E, Badarinath S, Graham C, Chen T, Gustafson T, Langer C (2005) Erbitux (Cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomised phase III trial. J Clin Oncol 23(16S): 3574
- Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E, Ramos L, Saltz LB (2002) Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that express the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 21: 536
- Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 20: 7
- Van Laethem JL, Raoul JL, Mitry E, Brezault C, Husseini F, Cals L, Vedovato JC, Mueser MM, Rougier P (2003) Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 22: 1058
Cited by
Sorted by citations
Items 501–540 of 540
Reviewmechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010)
Bi, Z. (2013) · The Chinese Journal of Modern Applied Pharmacy
Kanser hastalarında farmakogenetik uygulamaları ve farmakoekonomi
Baskın, Y., & Calibasi‐Kocal, G. (2011)
Métastases non résécables des cancers colorectaux
Fiore, F. D. (2008) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2008.04.003
Marginean, C. E., Zalcberg, J. R., Simes, J. R., Moore, M. J., Tebbutt, N. C., Price, T. J., Shapiro, J. D., Pavlakis, N., Gibbs, P., Hazel, G. A. V., et al. (2014)
Predictive Markers in Colon Cancer
Gerger, A., LaBonte, M. J., & Lenz, H. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9755-5_1
(2013) · CRC Press eBooks · doi:10.1201/b14587-17
Antibodies for Treatment of Metastatic Colorectal Cancer
Heinemann, V., & Stintzing, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-43063-8_9
Precision Oncology: Present Status and Perspectives
Tagliaferri, P., Arbitrio, M., Ierardi, A., Ciliberto, D., Martino, M. T. D., & Tassone, P. (2017) · Current clinical pathology · doi:10.1007/978-3-319-55661-1_2
Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer
Weickhardt, A. J. (2011) · Minerva Access (University of Melbourne)
Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study
Naguib, A., Cooke, J. C., Happerfield, L. C., Kerr, L., Luben, R., Ball, R. Y., Mitrou, P. N., McTaggart, A., & Arends, M. J. (2016)
Manceau, G., Laurent‐Puig, P., & Blons, H. (2012)
Discovery of prognostic markers in laryngeal cancer treated with radiotherapy
de Bruin, L. B. (2020) · doi:10.33612/diss.143832673
“of patients (%) Age – years Median (range) 63 (33-95) Gender Female 11 (21.”
BackgroundObaya, A., Mohammed, A. A., Rashied, H., Morsy, A. M., Osman, G., Allam, A. S., Elsayed, A. M., Harb, O. A., & Elsayed, W. S. H. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.4.1025
“The same findings were proved in many previous studies (Loupakis et al., 2009, Razis et al., 2008, Frattini et al., 2007, Mao et al., 2010, and Sood et al., 2012).”
ResultFiore, F. D. (2008) · Gastroentérologie Clinique et Biologique
Church, D. N., Midgley, R. S., & Kerr, R. S. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_9 · Cited by 1
Lièvre, A., & Laurent‐Puig, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8757
Wang, J., Zhang, Y., Wen, P., Ma, T., Wang, T., Song, W., & Zhang, B. (2022) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2022.3115
Williams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X., et al. (2023) · doi:10.1158/1078-0432.c.6529961
Williams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X., et al. (2023) · doi:10.1158/1078-0432.c.6529961.v1
Karim, H., Negm, O. H., Narmeen, A., & Ilyas, M. (2022) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/1410180
Biological mechanisms underlying susceptibility to traumatic stress
An, N. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240116an
Zhang, H., Li, X., Sun, W., Qin, H., Li, H., Yan, H., Wang, H., Zhang, X., Zhang, S., & Wang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12339-x
Malignant Epithelial Tumors of the Parotid Gland
Sakr, M. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-82069-4_14
Kahraman, S., ÇELEBİ, S. N. Ö., Kuratmer, A. D., Karahan, İ., Dede, D. S., ŞENDUR, M. A. N., Akıncı, M. B., Erol, C., Hızal, M., Bi̇lgi̇n, B., et al. (2025) · Journal of Oncological Sciences · doi:10.37047/jos.galenos.2025.2024.103340
Zhang, H., Li, X., Sun, W., Qin, H., Li, H., Yan, H., Wang, H., Zhang, X., Zhang, S., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.25815603
Zhang, H., Li, X., Sun, W., Qin, H., Li, H., Yan, H., Wang, H., Zhang, X., Zhang, S., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.25815089
Lima‐Fernandes, E. (2012) · theses.fr (ABES) · doi:10.70675/dc75b7cbz5451z4999za5e5z58fe19782ff1
S3-Leitlinie Kolorektales Karzinom
Pox, C. P., Reichermeier, S., Aretz, S., Graeven, U., Hüneburg, R., Hüppe, D., Koch, C., Köhne, C.-H., Kolligs, F. T., Ludwig, L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2853-0320
“Around 70% of KRAS exon 2 mutations are found in codon 12, a further 30% in codon 13 [1048].”
Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello
Mesı́a, R. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Seemann, H. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4083
Metadata
- Authors
- Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L.
- Affiliations
- Istituto Cantonale di Patologia (CH)
- Ospedale San Giovanni Bellinzona (CH)
- Corresponding author
- Frattini, M
- Venue
- British Journal of Cancer
- Published
- 2007-10
- Volume
- 97
- Issue
- 8
- Pages
- 1139-1145
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360431
- OpenAlex
- W2100589633
- Cited by
- 540
- References
- 31
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 14 · 2020: 16 · 2019: 14 · 2018: 9 · 2017: 15 · 2016: 20 · 2015: 30 · 2014: 38 · 2013: 38 · 2012: 63
- FWCI
- 33.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Oncosuisse
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- PTEN loss, cetuximab, metastatic colorectal cancer, EGFR overexpression, EGFR amplification, KRAS mutation, chromosome 7 polysomy, drug response prediction, predictive biomarkers
- MeSH terms
- Cetuximab, Adult, Aged, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Chromosomes, Human, Pair 7, Female, Gene Amplification, Humans, Immunohistochemistry, Male, Middle Aged, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Gene Expression, Proto-Oncogene Proteins p21(ras), In Situ Hybridization, Fluorescence, ras Proteins, Drug Resistance, Neoplasm, PTEN Phosphohydrolase, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
